NCT03544762
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: ESR1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 20 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients not suitable for hormone therapy after clinical assessment; Patients treated with oral or intravenous cytotoxic agent(s) during the same period of hormone therapy
https://ClinicalTrials.gov/show/NCT03544762